



**EFFECTIVE DATE:** 10|01|2015  
**POLICY LAST UPDATED:** 09|04|2018

## OVERVIEW

Ocriplasmin (Jetrea®) is a recombinant truncated form of human plasmin, a proteolytic enzyme that breaks down protein components at the vitreoretinal interface in the eye. Ocriplasmin is injected into the affected eye (intravitreal) as a single dose and can induce vitreous liquefaction and separation from the retina. Its proposed use is for the treatment of symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT).

## PRIOR AUTHORIZATION

Prior authorization is not required.

## POLICY STATEMENT

### BlueCHiP for Medicare

A single intravitreal injection of Ocriplasmin may be considered medically necessary for treatment of an eye with symptomatic vitreomacular adhesion (VMA) or vitreomacular traction.

The use of intravitreal Ocriplasmin is considered not covered in all other situations, including use of repeat injections of Ocriplasmin.

### Commercial Products

A single intravitreal injection of Ocriplasmin may be considered medically necessary for treatment of an eye with symptomatic vitreomacular adhesion (VMA) or vitreomacular traction.

The use of intravitreal Ocriplasmin is considered not medically necessary in all other situations, including use of repeat injections of Ocriplasmin.

## MEDICAL CRITERIA

Not applicable

## COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

## BACKGROUND

The vitreous is a gel-like fluid within the eye that adheres completely to the surface of the retina. The consistency of the vitreous and its adhesion to the retina are maintained by several proteins including collagen, laminin, and fibronectin. With aging, the proteins in the vitreous break down, resulting in liquefaction of the vitreous and eventual separation of the vitreous from the retina, a process called posterior vitreous detachment (PVD).

The process of vitreous detachment usually proceeds without incident, but sometimes the separation is not complete. The adhesion usually remains at sites where the bonds between the vitreous and retina are the strongest. In some cases, the adhesion can cause visual symptoms. The traction caused by the adherent vitreous can cause deformation of the retina, edema, and full-thickness macular holes (FTMH). Although the

terms are sometimes used synonymously, the International Vitreomacular Traction Study Group has defined vitreomacular adhesion (VMA) as adhesion at the macula without detectable changes in retinal morphology and vitreomacular traction (VMT) as adhesion with retinal morphologic changes but without full-thickness defect.<sup>1</sup> Both VMA and VMT can be focal or diffuse.

Symptoms can vary, but may include diminished visual acuity, distorted vision (metamorphopsia), and central field defect. Patients are usually observed until resolution or worsening, in which case vitrectomy is the standard treatment. Spontaneous release of VMA/VMT occurs in about 30% of cases over a period of 1 to 2 years, and observation is usually indicated because vitrectomy has risks and an almost certain occurrence of cataract in the years following the procedure

Ocriplasmin is a recombinant product that is a shortened form of the protease plasmin. Early studies of ocriplasmin were conducted in patients scheduled to have vitrectomy and established doses that showed some effect in inducing PVD.

### **CODING**

#### **BlueCHiP for Medicare and Commercial Products:**

The following HCPCS code is covered with one of the ICD10 codes listed in the code range below

**J7316:** Injection, Ocriplasmin, 0.125 mg

ICD10-CM Range: H43.821-H43.829

### **RELATED POLICIES**

None

### **PUBLISHED**

Provider Update, November 2018

Provider Update, June 2017

Provider Update, October 2016

Provider Update, August 2015

### **REFERENCES:**

1. Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. *Ophthalmology*. Dec 2013;120(12):2611-2619. PMID 24053995
2. Tzu JH, John VJ, Flynn HW, Jr., et al. Clinical course of vitreomacular traction managed initially by observation. *Ophthalmic Surg Lasers Imaging Retina*. May 1 2015;46(5):571-576. PMID 26057761
3. Jackson TL, Donachie PH, Sparrow JM, et al. United Kingdom National Ophthalmology Database Study of Vitreoretinal Surgery: Report 1; Case mix, complications, and cataract. *Eye (Lond)*. May 2013;27(5):644-651. PMID 23449509
4. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreal injection to facilitate posterior vitreous detachment before vitrectomy. *Ophthalmology*. Apr 2010;117(4):791-797. PMID 20138368
5. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. *Ophthalmology*. Jul 2009;116(7):1349-1355. PMID 19447497
6. Stalmans P, Delaey C, de Smet MD, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). *Retina*. Jul-Aug 2010;30(7):1122-1127. PMID 20616687
7. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Ocriplasmin for symptomatic vitreomacular adhesion. *TEC Assessments*. 2013;Volume 28:Tab 5. PMID 24066370
8. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. *N Engl J Med*. Aug 16 2012;367(7):606-615. PMID 22894573

9. Varma R, Haller JA, Kaiser PK. Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion: results of the Microplasmin for Intravitreal Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. *JAMA Ophthalmol.* Sep 2015;133(9):997-1004. PMID 26068086
10. Gandorfer A, Benz MS, Haller JA, et al. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. *Retina.* Jun 2015;35(6):1151-1157. PMID 25741816
11. Kaiser PK, Kampik A, Kuppermann BD, et al. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. *Retina.* Jun 2015;35(6):1111-1127. PMID 25635577
12. Novack RL, Staurengi G, Girach A, et al. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration. *Ophthalmology.* Apr 2015;122(4):796-802. PMID 25435217
13. Drener K, Girach A, Capone A, Jr. A randomized, placebo-controlled study of intravitreal ocriplasmin in pediatric patients scheduled for vitrectomy. *Retina.* Mar 2016;36(3):565-575. PMID 26398685
14. Hahn P, Chung MM, Flynn HW, Jr., et al. Safety profile of ocriplasmin for symptomatic vitreomacular adhesion: A comprehensive analysis of premarketing and postmarketing experiences. *Retina.* Jun 2015;35(6):1128-1134. PMID 25635575
15. Shah SP, Jeng-Miller KW, Fine HF, et al. Post-marketing survey of adverse events following ocriplasmin. *Ophthalmic Surg Lasers Imaging Retina.* Feb 2016;47(2):156-160. PMID 26878449
16. Chatziralli I, Theodossiadis G, Xanthopoulou P, et al. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. *Graefes Arch Clin Exp Ophthalmol.* Jul 2016;254(7):1247-1256. PMID 27137631
17. National Institute for Health and Care Excellence (NICE). Ocriplasmin for treating vitreomacular traction [TA297]. 2017; <https://www.nice.org.uk/guidance/ta297>. Accessed February 16, 2018.
18. Folk JC, Adelman RA, Flaxel CJ, et al. Idiopathic epiretinal membrane and vitreomacular traction Preferred Practice Pattern® guidelines. *Ophthalmology.* Jan 2016;123(1):P152-181. PMID 26578445

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

